SEARCH

SEARCH BY CITATION

References

  • Bender, R.A., Castle, M.C., Margileth, D.A. & Oliverio, V.T. (1977) The pharmacokinetics of [3H]-vincristine in man. Clinical Pharmacology and Therapeutics, 22, 430435.
  • Bennett, C.L., Sinkule, J.A., Schilsky, R.L., Senekjian, E. & Choi, K.E. (1987) Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer. Cancer Research, 47, 19521956.
  • Benson, A.B. III, Read, T.R., Goebel, S.L., Koeller, J.M. & Tormey, D.C. (1985) Correlations between leucocyte count and absolute granulocyte count in patients receiving cancer chemotherapy. Cancer, 56, 13501355.
  • Bergh, J., Wiklund, T., Erikstein, B., Fornander, T., Bengtsson, N.O., Malmstrom, P., Kellokumpu-Lehtinen, P., Anker, G., Bennmarker, H. & Wilking, N. (1998) Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients. Scandinavian Breast Group, Study SBG 9401. Annals of Oncology, 9, 403411.
  • Bergh, J., Wiklund, T., Erikstein, B., Lidbrink, E., Lindman, H., Malmstrom, P., Kellokumpu-Lehtinen, P., Bengtsson, N.O., Soderlund, G., Anker, G., Wist, E., Ottosson, S., Salminen, E., Ljungman, P., Holte, H., Nilsson, J., Blomqvist, C. & Wilking, N. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 Study. Lancet, 356, 13841391.
  • Blayney, D.W., LeBlanc, M.L., Grogan, T., Gaynor, E.R., Chapman, R.A., Spiridonidis, C.H., Taylor, S.A., Bearman, S.I., Miller, T.P. & Fisher, R.I. (2003) Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). Journal of Clinical Oncology, 21, 24662473.
  • Blumenthal, R.D., Reising, A., Leon, E. & Goldenberg, D.M. (2002) Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines. Clinical Cancer Research, 8, 13011309.
  • Bodey, G.P., Buckley, M., Sathe, Y.S. & Freireich, E.J. (1966) Quantitative relationships between circulating leucocytes and infection in patients with acute leukemia. Annals of Internal Medicine, 64, 328340.
  • Brigden, M.L., Mawji, K.B., Wilson, K.S. & Spinelli, J.J. (1991) The relationship between the absolute granulocyte count, platelet count and total leucocyte count in cancer chemotherapy patients. Clinical and Investigative Medicine. Medecine Clinique et Experimentale, 14, 395401.
  • Brosteanu, O., Hasenclever, D., Loeffler, M., Diehl, V. & Group, G.H. (2004) Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Annals of Hematology, 83, 176182.
  • Busse, D., Busch, F.W., Bohnenstengel, F., Eichelbaum, M., Fischer, P., Opalinska, J., Schumacher, K., Schweizer, E. & Kroemer, H.K. (1997) Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. Journal of Clinical Oncology, 15, 18851896.
  • Carpenter, J.T. Jr, Maddox, W.A., Laws, H.L., Wirtschafter, D.D. & Soong, S.J. (1982) Favorable factors in the adjuvant therapy of breast cancer. Cancer, 50, 1823.
  • Chatta, G.S., Price, T.H., Allen, R.C. & Dale, D.C. (1994) Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood, 84, 29232929.
  • Colijn, C. & Mackey, M.C. (2005a) A mathematical model of hematopoiesis: II. Cyclical neutropenia. Journal of Theoretical Biology, 237, 133146.
  • Colijn, C. & Mackey, M.C. (2005b) A mathematical model of hematopoiesis: I. Periodic chronic myelogenous leukemia. Journal of Theoretical Biology, 237, 117132.
  • Cortes, E.P., Holland, J.F., Wang, J.J., Sinks, L.F., Blom, J., Senn, H., Bank, A. & Glidewell, O. (1974) Amputation and adriamycin in primary osteosarcoma. New England Journal of Medicine, 291, 9981000.
  • Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dorken, B., Muller-Hermelink, H.K., Duhmke, E. & Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 23862395.
  • Dixon, D.O., Neilan, B., Jones, S.E., Lipschitz, D.A., Miller, T.P., Grozea, P.N. & Wilson, H.E. (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. Journal of Clinical Oncology, 4, 295305.
  • Engel, C., Loeffler, M., Schmitz, S., Tesch, H. & Diehl, V. (2000) Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Annals of Oncology, 11, 11051114.
  • Engel, C., Scholz, M. & Loeffler, M. (2004) A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood, 104, 23232331.
  • Friberg, L.E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M.O. (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. Journal of Clinical Oncology, 20, 47134721.
  • Gorschluter, M., Bohlen, H., Hasenclever, D., Diehl, V. & Tesch, H. (1995) Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Annals of Oncology, 6, 477482.
  • Gurney, H. (1996) Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. Journal of Clinical Oncology, 14, 25902611.
  • Gurney, H. (2002) How to calculate the dose of chemotherapy. British Journal of Cancer, 86, 12971302.
  • Hasenclever, D., Loeffler, M. & Diehl, V. (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Annals of Oncology, 7(Suppl. 4), 9598.
  • Hasenclever, D., Brosteanu, O., Gerike, T. & Loeffler, M. (2001) Modelling of chemotherapy: the effective dose approach. Annals of Hematology, 80(Suppl. 3), B8994.
  • Hortobagyi, G.N. (2001) Progress in systemic chemotherapy of primary breast cancer: an overview. Journal of the National Cancer Institute. Monographs, 30, 7279.
  • Horwich, A., Sleijfer, D.T., Fossa, S.D., Kaye, S.B., Oliver, R.T., Cullen, M.H., Mead, G.M., de Wit, R., de Mulder, P.H., Dearnaley, D.P., Cook, P.A., Sylvester, R.J. & Stenning, S.P. (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. Journal of Clinical Oncology, 15, 18441852.
  • Iyer, L. & Ratain, M.J. (1998) Pharmacogenetics and cancer chemotherapy. European Journal of Cancer, 34, 14931499.
  • Kloess, M., Wunderlich, A., Truemper, L., Pfreundschuh, M. & Loeffler, M. (2001) Relationship between prognostic factors for therapy and hematotoxicity in aggressive NHL. Annals of Hematology, 80(Suppl. III), B145B146 (abstract).
  • Kobayashi, K. & Ratain, M.J. (1993) Individualizing dosing of cancer chemotherapy. Seminars in Oncology, 20, 3042.
  • Li, F.P., Danahy, J. & Gelman, R. (1984) Utility of differential leucocyte counts in cancer management. JAMA, 252, 13121314.
  • Liang, L.B., Ma, Y.W., Zhou, X.S., Yang, J., Li, Y.C., Wang, Z., Zhou, L.P., Zhang, Y.P. & Zhao, Q.Z. (2003) Selective myelo-protection by MDR1 and MnSOD genes regulated by a specific promoter. Zhonghua Zhong Liu Za Zhi, 25, 1720.
  • Lohrmann, H.P. & Schreml, W. (1982) Cytotoxic drugs and the granulopoietic system. Recent Results in Cancer Research, 81, 1222.
  • von Minckwitz, G., Raab, G., Caputo, A., Schutte, M., Hilfrich, J., Blohmer, J.U., Gerber, B., Costa, S.D., Merkle, E., Eidtmann, H., Lampe, D., Jackisch, C., du Bois, A. & Kaufmann, M. (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. Journal of Clinical Oncology, 23, 26762685.
  • Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T. & Carbone, P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5, 649655.
  • Ostby, I., Kvalheim, G., Rusten, L.S. & Grottum, P. (2004) Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: effect of post-transplant G-CSF treatment. Journal of Theoretical Biology, 231, 6983.
  • Pettengell, R., Gurney, H., Radford, J.A., Deakin, D.P., James, R., Wilkinson, P.M., Kane, K., Bentley, J. & Crowther, D. (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood, 80, 14301436.
  • Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rube, C., Rudolph, C., Reiser, M., Hossfeld, D.K., Eimermacher, H., Hasenclever, D., Schmitz, N. & Loeffler, M. (2004a) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood, 104, 634641.
  • Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rudolph, C., Reiser, M., Hossfeld, D.K., Metzner, B., Hasenclever, D., Schmitz, N., Glass, B., Rube, C. & Loeffler, M. (2004b) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104, 626633.
  • Poikonen, P., Saarto, T., Lundin, J., Joensuu, H. & Blomqvist, C. (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. British Journal of Cancer, 80, 17631766.
  • Rankin, E.M., Mill, L., Kaye, S.B., Atkinson, R., Cassidy, L., Cordiner, J., Cruickshank, D., Davis, J., Duncan, I.D., Fullerton, W., Habeshaw, T., Kennedy, J., Kennedy, R., Kitchener, H., MacLean, A., Paul, J., Reed, N., Sarker, T., Soukop, M., Swapp, G.H. & Symonds, R.P. (1992) A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. British Journal of Cancer, 65, 275281.
  • Rechenberg, I. (1984) The evolution strategy: a mathematical model of Darwinian evolution. Springer Series in Synergetics, 22, 122132.
  • Rechenberg, I. (1994) Evolutionsstrategie ’94. Frommann-Holzboog, Stuttgart-Bad Cannstatt.
  • Rushing, D.A., Raber, S.R., Rodvold, K.A., Piscitelli, S.C., Plank, G.S. & Tewksbury, D.A. (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer, 74, 834841.
  • Sandstrom, M., Lindman, H., Nygren, P., Lidbrink, E., Bergh, J. & Karlsson, M.O. (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. Journal of Clinical Oncology, 23, 413421.
  • Scholz, M., Engel, C. & Loeffler, M. (2004) Modelling human granulopoiesis under poly-chemotherapy with G-CSF support. Journal of Mathematical Biology, 50, 397439.
  • Schwefel, H.P. (1984) Evolution strategies: a family of nonlinear optimization techniques based on imitating some principles of organic evolution. Annales of Operational Research, 1, 165167.
  • Shipp, M.A., Neuberg, D., Janicek, M., Canellos, G.P. & Shulman, L.N. (1995) High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. Journal of Clinical Oncology, 13, 29162923.
  • Sinkule, J.A. (1984) Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy, 4, 6173.
  • Sulkes, A. & Collins, J.M. (1987) Reappraisal of some dosage adjustment guidelines. Cancer Treatment Reports, 71, 229233.
  • Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Ruffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dolken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Muller, U. & Loeffler, M. (1998) Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group. Blood, 92, 45604567.
  • The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329, 987994.
  • Trillet-Lenoir, V., Green, J.A., Manegold, C., Von Pawel, J., Gatzemeier, U., Lebeau, B., Depierre, A., Johnson, P., Decoster, G., Matcham, J. & Ewen, C. (1995) Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up. European Journal of Cancer, 31A, 21152116.
  • Vainstein, V., Ginosar, Y., Shoham, M., Ranmar, D.O., Ianovski, A. & Agur, Z. (2005) The complex effect of granulocyte colony-stimulating factor on human granulopoiesis analyzed by a new physiologically-based mathematical model. Journal of Theoretical Biology, 234, 311327.
  • Wilson, W.H., Grossbard, M.L., Pittaluga, S., Cole, D., Pearson, D., Drbohlav, N., Steinberg, S.M., Little, R.F., Janik, J., Gutierrez, M., Raffeld, M., Staudt, L., Cheson, B.D., Longo, D.L., Harris, N., Jaffe, E.S., Chabner, B.A., Wittes, R. & Balis, F. (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood, 99, 26852693.
  • Wunderlich, A., Kloess, M., Reiser, M., Rudolph, C., Truemper, L., Bittner, S., Schmalenberg, H., Schmits, R., Pfreundschuh, M. & Loeffler, M. (2003) Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology, 14, 881893.